B
Bertrand Lell
Researcher at University of Tübingen
Publications - 154
Citations - 7249
Bertrand Lell is an academic researcher from University of Tübingen. The author has contributed to research in topics: Malaria & Plasmodium falciparum. The author has an hindex of 42, co-authored 135 publications receiving 6582 citations. Previous affiliations of Bertrand Lell include University of Vienna & Albert Schweitzer Hospital.
Papers
More filters
Journal ArticleDOI
First results of phase 3 trial of RTS,S/AS01 malaria vaccine in African children.
Selidji T Agnandji,Bertrand Lell,Bertrand Lell,Solange Soulanoudjingar,Solange Soulanoudjingar,José Francisco Fernandes,José Francisco Fernandes,Béatrice Peggy Abossolo,Béatrice Peggy Abossolo,Cornelia Conzelmann,Cornelia Conzelmann,Barbara Gaelle Nfono Ondo Methogo,Barbara Gaelle Nfono Ondo Methogo,Yannick Doucka,Yannick Doucka,Arnaud Flamen,Arnaud Flamen,Benjamin Mordmüller,Benjamin Mordmüller,Saadou Issifou,Saadou Issifou,Peter G. Kremsner,Peter G. Kremsner,Jahit Sacarlal,Pedro Aide,Miguel A. Lanaspa,John J. Aponte,Arlindo Nhamuave,Diana Quelhas,Quique Bassat,Sofia Mandjate,Eusebio Macete,Pedro L. Alonso,Salim Abdulla,Nahya Salim,Omar Juma,Mwanajaa Shomari,Kafuruki Shubis,Francisca Machera,Ali Hamad,Rose Minja,Ali Mtoro,Alma Sykes,Saumu Ahmed,Alwisa Urassa,Ali Ali,Grace Mwangoka,Marcel Tanner,Halidou Tinto,Umberto D'Alessandro,Hermann Sorgho,Innocent Valea,Marc Christian Tahita,William Kabore,Sayouba Ouedraogo,Yara Sandrine,Robert T. Guiguemdé,Jean-Bosco Ouédraogo,Mary J. Hamel,Simon Kariuki,Chris Odero,Martina Oneko,Kephas Otieno,Norbert Awino,Jackton Omoto,John Williamson,Vincent Muturi-Kioi,Kayla F. Laserson,Laurence Slutsker,Walter Otieno,Lucas Otieno,Otsyula Nekoye,Stacey M. O. Gondi,Allan Otieno,Bernhards Ogutu,Ruth Wasuna,Victorine Owira,David B. Jones,Agnes Akoth Onyango,Patricia Njuguna,Roma Chilengi,Pauline Akoo,Christine Kerubo,Jesse Gitaka,Charity Maingi,Trudie Lang,Ally Olotu,Benjamin Tsofa,Philip Bejon,Norbert Peshu,Kevin Marsh,Seth Owusu-Agyei,Kwaku Poku Asante,Kingsley Osei-Kwakye,Owusu Boahen,Samuel Ayamba,Kingsley Kayan,Ruth Owusu-Ofori,David Dosoo,Isaac Asante,George Adjei,Daniel Chandramohan,Brian Greenwood,John Lusingu,Samwel Gesase,Anangisye Malabeja,Omari Abdul,Hassan Kilavo,Coline Mahende,Edwin Liheluka,Martha M. Lemnge,Thor G. Theander,Chris Drakeley,Daniel Ansong,Tsiri Agbenyega,Samuel Adjei,Harry Owusu Boateng,Theresa Rettig,John Bawa,Justice Sylverken,David Sambian,Alex Agyekum,Larko Owusu,Francis Martinson,Irving F. Hoffman,Tisungane Mvalo,Portia Kamthunzi,Ruthendo Nkomo,Albans Msika,Allan Jumbe,Nelecy Chome,Dalitso Nyakuipa,Joseph Chintedza,W. Ripley Ballou,Myriam Bruls,Joe Cohen,Yolanda Guerra,Erik Jongert,Didier Lapierre,Amanda J. Leach,Marc Lievens,Opokua Ofori-Anyinam,Johan Vekemans,Terrell Carter,Didier Leboulleux,Christian Loucq,Afiya Radford,Barbara Savarese,David Schellenberg,Marla Sillman,Preeti Vansadia +150 more
TL;DR: The RTS,S/AS01 vaccine provided protection against both clinical and severe malaria in African children, and serious adverse events occurred with a similar frequency in the two study groups.
Journal ArticleDOI
A phase 3 trial of RTS,S/AS01 malaria vaccine in African infants.
Selidji T Agnandji,Selidji T Agnandji,Bertrand Lell,Bertrand Lell,José Francisco Fernandes,José Francisco Fernandes,Béatrice Peggy Abossolo,Béatrice Peggy Abossolo,Barbara Gaelle Nfono Ondo Methogo,Barbara Gaelle Nfono Ondo Methogo,Anita Lumeka Kabwende,Anita Lumeka Kabwende,Ayola A. Adegnika,Ayola A. Adegnika,Benjamin Mordmüller,Benjamin Mordmüller,Saadou Issifou,Saadou Issifou,Peter G. Kremsner,Peter G. Kremsner,Jahit Sacarlal,Pedro Aide,Miguel Lanaspa,John J. Aponte,Sonia Machevo,Sozinho Acácio,Helder Bulo,Betuel Sigaúque,Eusebio Macete,Pedro L. Alonso,Salim Abdulla,Salim Abdulla,Nahya Salim,Nahya Salim,Rose Minja,Rose Minja,Maxmillian Mpina,Maxmillian Mpina,Saumu Ahmed,Saumu Ahmed,Ali Ali,Ali Ali,Ali Mtoro,Ali Mtoro,Ali Hamad,Ali Hamad,Paul Mutani,Paul Mutani,Marcel Tanner,Marcel Tanner,Halidou Tinto,Umberto D'Alessandro,Hermann Sorgho,Innocent Valea,Biebo Bihoun,Issa Guiraud,Berenger Kaboré,Olivier Sombié,Robert T. Guiguemdé,Jean-Bosco Ouédraogo,Mary J. Hamel,Simon Kariuki,Martina Oneko,Chris Odero,Kephas Otieno,Norbert Awino,Meredith McMorrow,Vincent Muturi-Kioi,Kayla F. Laserson,Laurence Slutsker,Walter Otieno,Lucas Otieno,Nekoye Otsyula,Stacey M. O. Gondi,Allan Otieno,Victorine Owira,Esther Oguk,George Odongo,Jon Ben Woods,Bernhards Ogutu,Patricia Njuguna,Roma Chilengi,Pauline Akoo,Christine Kerubo,Charity Maingi,Trudie Lang,Ally Olotu,Philip Bejon,Kevin Marsh,Gabriel Mwambingu,Seth Owusu-Agyei,Kwaku Poku Asante,Kingsley Osei-Kwakye,Owusu Boahen,David Dosoo,Isaac Asante,George Adjei,Evans Kwara,Daniel Chandramohan,Brian Greenwood,John Lusingu,John Lusingu,John Lusingu,Samwel Gesase,Samwel Gesase,Samwel Gesase,Anangisye Malabeja,Anangisye Malabeja,Anangisye Malabeja,Omari Abdul,Omari Abdul,Omari Abdul,Coline Mahende,Coline Mahende,Coline Mahende,Edwin Liheluka,Edwin Liheluka,Edwin Liheluka,Lincoln Malle,Lincoln Malle,Lincoln Malle,M.M. Lemnge,M.M. Lemnge,M.M. Lemnge,Thor G. Theander,Thor G. Theander,Thor G. Theander,Chris Drakeley,Chris Drakeley,Chris Drakeley,Daniel Ansong,Tsiri Agbenyega,Samuel Adjei,Harry Owusu Boateng,Theresa Rettig,John Bawa,Justice Sylverken,David Sambian,Anima Sarfo,Alex Agyekum,Francis Martinson,Irving F. Hoffman,Tisungane Mvalo,Portia Kamthunzi,Rutendo Nkomo,Tapiwa Tembo,Gerald Tegha,Mercy Tsidya,Jane Kilembe,Chimwemwe Chawinga,W. Ripley Ballou,Joe Cohen,Yolanda Guerra,Erik Jongert,Didier Lapierre,Amanda J. Leach,Marc Lievens,Opokua Ofori-Anyinam,Aurélie Olivier,Johan Vekemans,Terrell Carter,David C. Kaslow,Didier Leboulleux,Christian Loucq,Afiya Radford,Barbara Savarese,David Schellenberg,Marla Sillman,Preeti Vansadia +168 more
TL;DR: The RTS,S/AS01 vaccine coadministered with EPI vaccines provided modest protection against both clinical and severe malaria in young infants.
Journal ArticleDOI
Efficacy and safety of RTS,S/AS01 malaria vaccine with or without a booster dose in infants and children in Africa: final results of a phase 3, individually randomised, controlled trial.
Emmanuel B. Bache,Selidji T Agnandji,Bertrand Lell,José Francisco Fernandes,Béatrice Peggy Abossolo,Anita Lumeka Kabwende,Ayola A. Adegnika,Benjamin Mordmüller,Peter G. Kremsner,Marguerite Massinga Loembe,Abraham Alabi,Saadou Issifou +11 more
TL;DR: RTS,S/AS01 prevented a substantial number of cases of clinical malaria over a 3–4 year period in young infants and children when administered with or without a booster dose, and Efficacy was enhanced by the administration of a boosters in both age categories.
Journal ArticleDOI
Efficacy and safety of intermittent preventive treatment with sulfadoxine-pyrimethamine for malaria in African infants: a pooled analysis of six randomised, placebo-controlled trials
John J. Aponte,David Schellenberg,Andrea Egan,Alasdair Breckenridge,Ilona Carneiro,Julia A Critchley,Ina Danquah,Alexander N. O. Dodoo,Robin Kobbe,Bertrand Lell,Bertrand Lell,Jürgen May,Zul Premji,Sergi Sanz,Esperanza Sevene,Rachida Soulaymani-Becheikh,Peter Winstanley,Samuel Adjei,Sylvester D. Anemana,Daniel Chandramohan,Saadou Issifou,Saadou Issifou,Frank P. Mockenhaupt,Seth Owusu-Agyei,Brian Greenwood,Martin P. Grobusch,Martin P. Grobusch,Peter G. Kremsner,Peter G. Kremsner,Eusebio Macete,Hassan Mshinda,Robert D. Newman,Laurence Slutsker,Marcel Tanner,Pedro L. Alonso,Clara Menéndez +35 more
TL;DR: IPTi with sulfadoxine-pyrimethamine was safe and efficacious across a range of malaria transmission settings, suggesting that this intervention is a useful contribution to malaria control.
Journal ArticleDOI
The Effect of Dosing Regimens on the Antimalarial Efficacy of Dihydroartemisinin-Piperaquine: A Pooled Analysis of Individual Patient Data
Jane Achan,Ishag Adam,Emmanuel Arinaitwe,Elizabeth A. Ashley,Ghulam Rahim Awab,Ghulam Rahim Awab,Mamadou S. Ba,Karen I. Barnes,Quique Bassat,Steffen Borrmann,Steffen Borrmann,Teun Bousema,Teun Bousema,Prabin Dahal,Umberto D'Alessandro,Umberto D'Alessandro,Timothy M. E. Davis,Arjen M. Dondorp,Grant Dorsey,Chris Drakeley,Caterina I. Fanello,Babacar Faye,Jennifer A. Flegg,Oumar Gaye,Peter W. Gething,Raquel González,Philippe J Guerin,Simon I. Hay,Tran Tinh Hien,Tran Tinh Hien,Bart Janssens,Moses R. Kamya,Corine Karema,Harin Karunajeewa,Moussa Koné,Bertrand Lell,Kevin Marsh,Kevin Marsh,Mayfong Mayxay,Mayfong Mayxay,Clara Menéndez,Petra F. Mens,Martin M Meremikwu,Clarissa Moreira,Clarissa Moreira,Ivo Mueller,Ivo Mueller,Carolyn Nabasumba,Michael Nambozi,Jean Louis Ndiaye,Paul N. Newton,Paul N. Newton,Thuy Nguyen,François Nosten,François Nosten,Christian Nsanzabana,Sabah A. Omar,Jean-Bosco Ouédraogo,Louis K. Penali,Mbaye Pene,Aung Pyae Phyo,Patrice Piola,Ric N. Price,Ric N. Price,P. Sasithon,Philip J. Rosenthal,Albert Same-Ekobo,Patrick Sawa,Henk D. F. H. Schallig,Seif Shekalaghe,Carol Hopkins Sibley,Jeff Smith,Frank Smithuis,Anyirékun Fabrice Somé,Kasia Stepniewska,Ambrose O. Talisuna,Joel Tarning,Joel Tarning,Emiliana Tjitra,Roger Tine,Halidou Tinto,Neena Valecha,Michel Van Herp,Michèle van Vugt,Nicholas J. White,Nicholas J. White,Charles J. Woodrow,William Yavo,Adoke Yeka,Issaka Zongo +89 more
TL;DR: In this paper, the influence of different dosing schedules on Dihydroartemisinin-piperaquine (DP) clinical efficacy was investigated, and a multivariable model was used to identify risk factors for parasite recrudescence.